Ascentage Pharma (06855) Lisaftoclax Receives Breakthrough Therapy Designation for the Treatment of Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Zhitong Finance APP News, Ascentage Pharma (06855) announced that its original Class 1 new drug Bcl-2 inhibitor Lisunto (generic name: lisaftoclax, R&D code: APG-2575) has been included by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the "Breakthrough Therapy Designation" list for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in combination with acalabrutinib.